CTLA-4 Antibodies

Santa Cruz Biotechnology offers a broad range of CTLA-4 monoclonal antibodies for immunology and cancer biology research. CTLA-4 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CTLA-4, or cytotoxic T-lymphocyte-associated protein 4, is a critical immune checkpoint that plays a vital role in regulating T cell activation and maintaining immune homeostasis. By inhibiting T cell responses, CTLA-4 is essential for preventing autoimmunity and promoting tolerance to self-antigens. The importance of CTLA-4 in cancer therapy has been demonstrated by the development of CTLA-4 inhibitors, which have shown promise in enhancing anti-tumor immunity. Researchers can investigate immune regulation mechanisms using specific CTLA-4 detection methods. Understanding CTLA-4 function continues to reveal new insights into immune system regulation and potential therapeutic strategies. Current studies focusing on CTLA-4 are advancing our knowledge of immune checkpoint pathways and their role in disease. Santa Cruz Biotechnology monoclonal antibodies for CTLA-4 support researchers worldwide in advancing immunotherapy and cancer treatment breakthroughs.